| 产品编号 | bs-15088R |
| 英文名称 | C1s Rabbit pAb |
| 中文名称 | 补体C1S链多肽抗体 |
| 别 名 | EDSPD2; C1s; C1sa; r-gsp; C1S_HUMAN; C1 esterase; Complement component 1 subcomponent s; 3.4.21.42; CS1A_MOUSE; C1s1; Complement C1s-A subcomponent; Complement component 1 subcomponent s-A; Complement component 1, S subcomponent 1; C1S_RAT; |
| 研究领域 | 细胞生物 免疫学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 克 隆 号 | |
| 交叉反应 | Human,Mouse (predicted: Rat,Horse) |
| 产品应用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 47/75 kDa |
| 细胞定位 | 细胞外基质 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human C1s : 251-350/688 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
The complement component proteins, C1, C3, C4, and C5, are potent anaphylatoxins that are released during complement activation. Binding of these proteins to their respective G protein-coupled receptors induces proinflammatory events, such as cellular degranulation, smooth muscle contraction, arachidonic acid metabolism, cytokine release, leukocyte activation, and cellular chemotaxis. C1q, together with proenzymes C1r and C1s, yield C1, the first component of the classical pathway of the serum complement system. C1 consists of a calcium dependent trimolecular complex of C1r, C1s and C1q in a 2:2:1 ratio. Activated C1s is in the form of a disulfide-linked heterodimer consisting of a heavy chain and a light chain. Defects in the gene encoding for C1s can cause selective C1s deficiency, a disorder characterized by early onset of various autoimmune diseases. Function: C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4. Subunit: C1 is a calcium-dependent trimolecular complex of C1q, C1r and C1s in the molar ration of 1:2:2. Activated C1s is an disulfide-linked heterodimer of a heavy chain and a light chain. Post-translational modifications: The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains. DISEASE: Defects in C1S are the cause of complement component C1s deficiency (C1SD) [MIM:613783]. A rare defect resulting in C1 deficiency and impaired activation of the complement classical pathway. C1 deficiency generally leads to severe immune complex disease with features of systemic lupus erythematosus and glomerulonephritis. Similarity: Belongs to the peptidase S1 family. Contains 2 CUB domains. Contains 1 EGF-like domain. Contains 1 peptidase S1 domain. Contains 2 Sushi (CCP/SCR) domains. SWISS: P09871 Gene ID: 716 Database links: Entrez Gene: 716 Human Entrez Gene: 50908 Mouse Omim: 120580 Human SwissProt: P09871 Human SwissProt: Q8CG14 Mouse Unigene: 458355 Human Unigene: 4037 Rat |
| 产品图片 |
Sample: Heart (Mouse) Lysate at 40 ug
Primary: Anti-C1s (bs-15088R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 47/75 kD
Observed band size: 55 kD
Sample:
Pancreas (Mouse) Lysate at 40 ug
Primary: Anti-C1s (bs-15088R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 47/75 kD
Observed band size: 47 kD
Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-C1S Polyclonal Antibody, Unconjugated(bs-15088R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
